TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CytoMed Therapeutics Limited ( (GDTC) ) has shared an update.
On November 6, 2025, CytoMed Therapeutics announced securing a non-dilutive investment from ICH Capital for its subsidiary LongevityBank, which focuses on autologous therapies. The investment will help LongevityBank expand its personalized cellular banking services. Additionally, CytoMed is exploring a new strategy in China, leveraging recent regulatory changes to introduce its allogeneic gamma delta T cell platform. This strategic move is expected to enhance CytoMed’s market positioning in Southeast Asia and China, potentially benefiting stakeholders by expanding treatment options and improving accessibility to innovative cancer therapies.
The most recent analyst rating on (GDTC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on CytoMed Therapeutics Limited stock, see the GDTC Stock Forecast page.
Spark’s Take on GDTC Stock
According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral.
The overall stock score is primarily impacted by the company’s weak financial performance, characterized by declining revenues and cash flow deficits. Technical analysis provides some positive signals, but these are overshadowed by poor valuation metrics, including a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on GDTC stock, click here.
More about CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a Singapore-based clinical stage biopharmaceutical company that focuses on developing novel, affordable donor-derived cell-based immunotherapies for treating a wide range of cancers, including both blood and solid tumors. The company leverages its proprietary technologies, such as gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create allogeneic immunotherapies inspired by the success of CAR-T therapies.
Average Trading Volume: 72,882
Technical Sentiment Signal: Sell
Current Market Cap: $23.35M
For a thorough assessment of GDTC stock, go to TipRanks’ Stock Analysis page.